PerkinElmer acquires Geospiza
Links up with bioinformatics firm
PerkinElmer has bought Geospiza, a Seattle, US-based developer of software for the management of genetic analysis and laboratory workflows, for an undisclosed sum.
The addition of Geospiza to PerkinElmer’s DNA sequencing and analysis services will give scientists access to sequencing services and analysis and visualisation software, delivered through a web-based secure cloud computing capability. This will enable researchers to explore the genomic origins of disease more effectively, and help address the need to manage knowledge and drive scientific productivity, said Waltham, US-based PerkinElmer.
‘Genomic information is becoming increasingly important in understanding and treating disease. Making sense of the unprecedented volumes of data generated by next generation sequencing and other biological measurements is critical to improve the disease diagnosis process and drug discovery,’ said Richard Begley, president, Emerging Technologies, PerkinElmer.
He added: ‘The acquisition of Geospiza, along with existing software in our various diagnostic businesses, gives PerkinElmer a strong platform for offerings in nucleic acid testing. We look forward to expanding our family of genetic analysis offerings in research, drug discovery and diagnostics.’
Geospiza’s clients include biotechnology and pharmaceutical companies, universities, researchers, contract and diagnostic service laboratories involved in genetic testing and manufacturing biotherapeutics.
Geospiza is the developer of GeneSifter software, providing integrated solutions for Next Generation Sequencing analysis and LIMS.